Corindus Vascular Robotics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Corindus Vascular Robotics, Inc.
The Siemens Healthineers subsidiary is planning to create networks of CorPath GRX robotic intervention systems that will expand patient access to urgent interventions and reduce radiation exposure for both the patient and interventionalists.
Market Brief: Robotic Surgery Systems Market Will Reach $9.7Bn By 2023; Driven By Innovation, Procedure Volume Growth And Access To Emerging Markets
The global market for robotic surgery systems is expected to grow at a CAGR of 16%, reaching $9.7bn by 2023, driven by continued innovation, access to emerging markets and rising demand.
Siemens Healthineers ̶ an engineering company by background – sees itself well positioned to benefit from the markets’ movement towards digital, workflows, robotics and minimally-invasive procedures. As such, it has advantages over pharma companies in being able to deliver better patient outcomes at lower cost and more effectively.
The physician who led the first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.